{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:15:25Z","timestamp":1791378925545,"version":"4.3.2"},"reference-count":22,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Synthetic cannabinoids (SCs), a class of new psychoactive substances (NPS) commonly known as \u201cspice,\u201d has rapidly gained popularity and become the most ubiquitous NPS on the illegitimate drug market. SCs, unlike natural cannabis (NC), are not controlled by international drug conventions, posing a significant risk to public health. These substances are easily accessible, relatively inexpensive, and challenging to detect in routine drug screenings. The existing literature provides strong evidence of an association between NC use and psychosis, but there is significantly less data on SC psychosis. We present a clinical case report of a 51-year-old African American female with no known psychiatric history who was admitted to the inpatient psychiatric unit after reported paranoia and altered mental status for the preceding six days. During hospitalization, she exhibited disorganization, persecutory delusions, extreme agitation, and bizarre behaviors that included the concealment of a set of stolen keys in her vagina, necessitating an ethics consult. After consideration of differentials, the patient was diagnosed with substance-induced psychotic disorder secondary to SC. The patient was stabilized on 3 mg Risperidone at bedtime. After 16-day hospitalization, she reached her baseline and later revealed that she had recently smoked SC for the first time. The primary goal of this case is to highlight the sequelae of SC-associated psychosis. A SC-associated psychosis could drastically vary from NC and is often undetectable on a typical UDS, which may result in a lifelong primary psychotic disorder misdiagnosis.<\/jats:p>","DOI":"10.64719\/pb.4481","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"33-39","source":"Crossref","is-referenced-by-count":2,"title":["New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report"],"prefix":"10.64719","volume":"54","author":[{"given":"Ahmed","family":"Alhassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari R","family":"Prahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley G","family":"Burk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E","family":"Fargason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badari","family":"Birur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ (Clinical research ed). 2005;330(7481):11.","DOI":"10.1136\/bmj.38267.664086.63"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin. 2016;42(5):1262\u20131269.","DOI":"10.1093\/schbul\/sbw003"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;370(9584):319\u2013328.","DOI":"10.1016\/S0140-6736(07)61162-3"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Martinotti G, Santacroce R, Papanti D, Elgharably Y, Prilutskaya M, Corazza O. Synthetic cannabinoids: Psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets. 2017;16(5):567\u2013575.","DOI":"10.2174\/1871527316666170413101839"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Auw\u00e4rter V, Dresen S, Weinmann W, M\u00fcller M, P\u00fctz M, Ferreir\u00f3s N. \u2018Spice\u2019 and other herbal blends: Harmless incense or cannabinoid designer drugs. J Mass Spectrom. 2009;44(5):832\u2013837.","DOI":"10.1002\/jms.1558"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Elsohly MA, Gul W, Wanas AS, Radwan MM. Synthetic cannabinoids: Analysis and metabolites. Life Sci. 2014;97(1):78\u201390.","DOI":"10.1016\/j.lfs.2013.12.212"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"D\u2019Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis\/schizophrenia: Human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):413\u2013431.","DOI":"10.1007\/s00406-009-0024-2"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Di Forti M, Quattrone D, Freeman TP et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry. 2019;6(5):427\u2013436.","DOI":"10.1016\/S2215-0366(19)30048-3"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Spaderna M, Addy PH, D\u2019Souza DC. Spicing things up: Synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525\u2013540.","DOI":"10.1007\/s00213-013-3188-4"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1\u201313.","DOI":"10.3109\/15563650.2015.1110590"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Winstock A, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29(6):698\u2013703.","DOI":"10.1177\/0269881115574493"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Quattrone D, Ferraro L, Tripoli G et al. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study. Psychological Medicine. 2021;51(8):1329\u20131337.","DOI":"10.1017\/S0033291720000082"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ricci V, Ceci F, Di Carlo F et al. Cannabis use disorder and dissociation: A report from a prospective first-episode psychosis study. Drug Alcohol Depend. 2021;229(Pt A):109118.","DOI":"10.1016\/j.drugalcdep.2021.109118"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bhavsar V. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia. Evid Based Ment Health. 2015;18(3):84.","DOI":"10.1136\/eb-2014-102040"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Deng H, Verrico CD, Kosten TR, Nielsen DA. Psychosis and synthetic cannabinoids. Psychiatry Research. 2018;268:400\u2013412.","DOI":"10.1016\/j.psychres.2018.08.012"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Cottencin O, Rolland B, Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): Review of literature. Curr Pharm Des. 2014;20(25):4106\u20134111.","DOI":"10.2174\/13816128113199990622"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Walsh KB, Andersen HK. Molecular pharmacology of synthetic cannabinoids: Delineating CB1 receptor-mediated cell signaling. Int J Mol Sci. 2020;21(17)","DOI":"10.3390\/ijms21176115"},{"key":"ref18","unstructured":"US Drug Enforcement Administration DCD. Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS; Published. 2016 https:\/\/www.nflis.deadiversion.usdoj.gov\/DesktopModules\/ReportDownloads\/Reports\/NFLIS-SR-SynthCannabinoidCathinone.pdf. Accessed."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Klein TA, Dilley JA, Graves JM, Liebelt EL. Synthetic cannabinoid poisonings and access to the legal cannabis market: Findings from US national poison centre data 2016\u20132019. Clin Toxicol (Phila). 2022;60(9):1024\u20131028.","DOI":"10.1080\/15563650.2022.2099887"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Roberto AJ, Lorenzo A, Li KJ et al. First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone. Case Rep Psychiatry. 2016;2016:7257489.","DOI":"10.1155\/2016\/7257489"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: A case series. The American Journal of Psychiatry. 2011;168(10):1119.","DOI":"10.1176\/appi.ajp.2011.11010176"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Iseger TA, Bossong MG. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research. 2015;162(1\u20133):153\u2013161.","DOI":"10.1016\/j.schres.2015.01.033"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:32:07Z","timestamp":1791315127000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/new-onset-prolonged-psychosis-following-synthetic-cannabinoid-use-in-an-older-patient-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4481","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}